Evidence map›Paper›PMID 40831923›Full record

ArticleFrontiers in oncology2025

A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.

Thanh Tai Duong, Danny De Sarno, Hatim Fakir, Glenn Bauman, Martin Martinov, Rowan M Thomson, Ting-Yim Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thanh Tai Duong *Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Danny De Sarno *Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Hatim FakirOncology Department, University of Western Ontario, London, ON, Canada.
Glenn BaumanOncology Department, University of Western Ontario, London, ON, Canada.
Martin MartinovPhysics Department, Carleton University, Ottawa, ON, Canada.
Rowan M ThomsonPhysics Department, Carleton University, Ottawa, ON, Canada.
Ting-Yim LeeRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Theranostics integrates diagnostic imaging (e.g., Methods: Dynamic PET/CT scans obtained with Results: Voxel-wise LDV graphical analysis demonstrated strong linearity, with an interpatient mean Conclusion: We developed a framework for personalized TRT dose calculations using pre-treatment diagnostic PET/CT scans, eliminating the need for post-treatment SPECT/CT scans via the LDV-based method. This approach addresses variability in tumor and organ-at-risk doses from one-size-fits-all radioligand dosing, enabling optimized pre-treatment planning and integration with external beam radiation therapy (EBRT) or brachytherapy, if indicated, for precise and effective therapy. This method shows promise but requires further validation through larger studies and direct comparison with post-treatment dosimetry to confirm its accuracy.

Indexed as

177Lu-PSMA-617biological effective dose (BED)Monte Carlo simulationpersonalized dosimetrytargeted radioligand therapy (TRT)tracer kinetics

Identifiers

PMID40831923
PMCPMC12358388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.